A new cost-saving in vivo shuttle session on validated syngeneic mouse tumor models
09 / 08 / 2020
07 / 09 / 2020
Because of metastatic development of the disease, among other characteristics, and regardless of survival data, breast cancer was shown to be particularly difficult to treat. However, metastases as well as resistance to therapies continue to be a great challenge and the development of new therapeutic strategies is increasingly necessary.
06 / 18 / 2020
We will be attending the AACR Virtual Annual Meeting, from June 22 to 24, 2020 to present our posters featuring our capacities / platforms that support drug discovery in Immuno-Oncology.
06 / 18 / 2020
We will be attending the AACR Virtual Annual Meeting, from June 22 to 24, 2020 to present our posters featuring our capacities / platforms that support drug discovery in Immuno-Oncology.
06 / 11 / 2020
Take advantage of our upcoming in vitro shuttle session scheduled in early July on our validated M2 macrophage suppression assay, to assess novel immunotherapeutics in time and cost-effective manner.
05 / 14 / 2020
How about an opportunity to assess your compounds in a comprehensive and cost-effective manner?
04 / 16 / 2020
Explicyte’s expertise and advanced technologies have been harnessed so as to build a cell-based service platform for immuno-oncology (IO) assessment and drug discovery.